X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Letybo (Botulinum toxin type A) is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines in adult patients.
Lead Product(s): Botulinum Toxin A
Therapeutic Area: Dermatology Product Name: Letybo
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Hugel
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2024
Details:
Anaprozole Sodium Enteric-coated Tablet is currently the first and only proton pump inhibitor, which is investigated for the treatment of duodenal ulcer.
Lead Product(s): Anaprozole Sodium
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2023
Details:
Combio Pharmaceutical product pipeline already has 12 products under development, of which KM257/252 is a bispecific antibody drug for cholangiocarcinoma, breast cancer, gastroesophageal cancer, etc.
Lead Product(s): KM257
Therapeutic Area: Oncology Product Name: KM257
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Xuanzhu Biopharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 27, 2021
Details:
The Trials are random, parallel dose exploration studies with three dosage groups (high, middle and low dosage) to explore the best treatment regimen of Favipiravir for COVID-19 patients.
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2020
Details:
The results of the completed phase II clinical trial showed that Anaprazole is effective in treating duodenal ulcer, conducive to ulcer healing and relieves ulcer-related symptoms.
Lead Product(s): Anaprazole sodium
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
